TENX plans future trials enrolling sicker patients
TENX says recent trial data missed the primary endpoint but showed strong biological effects, especially in sicker patients, including NT-proBNP and pressure reductions. Future trials will enroll less healthy patients with protocol adjustments to better demonstrate efficacy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.